Sam Smith, PhD, discusses the relationship between menopausal symptoms and non-adherence in patients receiving tamoxifen.
Sam Smith, PhD, from University of Leeds, discusses the association between menopausal symptoms and adherence for patients with breast cancer taking tamoxifen.
This trial matched a patient’s adherence to the menopausal symptoms they experienced. Symptoms measured were headaches, nausea and vomiting, gynecologic issues, and hot flashes. Although no association was found between gynecologic symptoms or hot flashes and nonadherence, researchers did find that patients who experienced nausea and vomiting or headaches were less likely to adhere to their medication.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.